Stock Ratings / Health Care / IMCR / insiders

REPL (46) NVAX (56) MAZE (45) LYCA (59) ⌘ Pro Terminal →

Immunocore Holdings plc (IMCR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$31.27 -4.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.98

Immunocore Holdings plc (IMCR) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.61B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.98 (-0.93%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMCR)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY IMCR SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (26% of score)

20D Institutional Volume Accumulation (±9.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$29.39+0% Next Q

Q2 (-2Q)

Grade E$29.40+5.4% Next Q

Q3 (-1Q)

Grade E$30.98+0.9% Next Q

Current

Grade E$31.27-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMCR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMCR currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.37) and Max Pain ($32.83) forces dealer call-delta covering toward $42.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

IMCR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (IMCR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on IMCR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMCR)

✓Walkthrough of IMCR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.04%📐 HORIZONTAL RANGE

2026-10-30O $31.00H $31.44L $30.13C $31.27VOL 290.2K

RES: $40.26SUP: $26.41SMA50: $32.37SMA200: $31.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMCR Butterfly Map → + Track IMCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +29.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMCR)

Health Care Rank #908 of 1016 ⚔️ REPL vs IMCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMCR vs. REPL, NVAX, MAZE, LYCA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immunocore Holdings plc (IMCR) ranks #908 by composite RQD confidence (31/100, grade E) and #297 by equity capitalization ($1.61B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IMCR at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMCR ACTIVE Immunocore Holdings plc	E	31/100	—	96.0%	-35.0%	-4.11%	$1.61B	Benchmark Subject
REPL Replimune Group Inc.	D	46/100	—	—	-35.0%	+8.28%	$1.65B	/repl-vs-imcr →
NVAX Novavax Inc.	D+	56/100	3.9x	93.5%	85.0%	+1.45%	$1.73B	/nvax-vs-imcr →
MAZE Maze Therapeutics Inc.	D	45/100	—	—	-35.0%	+0.63%	$1.77B	/maze-vs-imcr →
LYCA Lycia Therapeutics Inc.	C-	59/100	—	—	—	+10.70%	$1.44B	/lyca-vs-imcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671927

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immunocore Holdings plc (IMCR) reported GAAP revenue of $400.0M (+29.0% vs. FY2024 revenue of $310.2M , and +60.4% cumulative change since FY2023) , GAAP net income of -$35.5M, operating cash flow of -$10.7M, and free cash flow of -$15.1M (-172.1% YoY). On the balance sheet, IMCR closed FY2025 with $1.07B in total assets against $0 in total debt (Altman Z-Score: 1.40, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$400.0M	-$35.5M	-$10.7M	-$15.1M	$1.07B	—
FY2024 (FY)	2024-12-31	$310.2M	-$51.1M	$26.1M	$20.9M	$1.01B	—
FY2023 (FY)	2023-12-31	$249.4M	-$55.3M	$2.9M	$2.9M	—	—

3. IMCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Immunocore Holdings plc (NASDAQ: IMCR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $31.27 (-4.11% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMCR ranks #908 in composite RQD confidence.

How does IMCR compare to REPL and NVAX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMCR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, REPL (Replimune Group Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.65B) and NVAX (Novavax Inc.) posts a D+ grade (56/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.73B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMCR?

Per IMCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671927), Immunocore Holdings plc generated $400.0M in revenue (+29.0% YoY), -$35.5M in net income, and -$15.1M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMCR trading relative to its 50-day, 200-day, and 52-week technical levels?

IMCR last traded at $31.27 (-4.11% on volume of 1,287,159 shares), positioning the stock -3.40% below its 50-day simple moving average ($32.37) and -1.54% below its 200-day simple moving average ($31.76). Across its 52-week range of $27.50 to $40.72, IMCR sits at the 28.5% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($28.39 to $34.15).

IMCR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are IMCR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies IMCR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: IMCR RQD Cockpit IMCR 12M Forecast IMCR Earnings & Move IMCR Dividends & DRIP IMCR Insiders & 13F IMCR Whale Options IMCR Profit Sankey IMCR News & Why